Evicenter
P&T meetings

SKY-0515

Huntington's disease

Last updated
211 sources

Product information and disease descriptionProduct descriptionProduct informationDosing and administration

Dosage

4 evidence topics · 3 sources

SKY-0515-001 Part C: randomized period dosing

“A single dose of SKY-0515 or placebo will be administered orally once daily on Days 1 to 28 (Cycle 1), Days 29 to 56 (Cycle 2) and Days 57 to 84 (Cycle 3).” (opens the source at this quote in a new tab)

SKY-0515-001 Part C: extension dosing

“followed by a twelve-month blinded Extension period during which all participants receive active treatment at either a low or high dose (4mg or 9mg), with the majority of patients on the 9 mg dose.” (opens the source at this quote in a new tab)

FALCON-HD: dose levels

“Eligible patients receive once-daily oral SKY-0515 at one of three dose levels or placebo.” (opens the source at this quote in a new tab)

Open-label extension: dose

“Dosage Level(s): 9mg Route of Administration: Oral Dosage Frequency: Once daily” (opens the source at this quote in a new tab)

Proposed commercial dose and dose adjustment

No evidence found.